Table 2.
Univariate linear regression analysis relating the levels of anxiety with the continuous and categorical variables.
| Variable | Coefficient | p value |
|---|---|---|
| Age (decades) | −3.19 | 0.116 |
| Sex (female) | +10.79 | 0.031 |
| Treatment experienced | −13.15 | 0.152 |
| Number of previous injections | −0.02 | 0.922 |
| Subjective number of previous injections | −0.09 | 0.617 |
| Binocular BCVA | +13.96 | 0.139 |
| Improvement in binocular BCVA | +30.3 | 0.093 |
| Number of eyes treated (one) | +0.54 | 0.916 |
| Change in treatment (no) | +4.30 | 0.392 |
| Anti-VEGF | ||
| Bevacizumab | Reference | |
| Ranibizumab | −7.11 | 0.228 |
| Aflibercept | −14.59 | 0.046 |
| Treated disease | ||
| AMD | Reference | |
| DME | −0.36 | 0.947 |
| RVO | −4.51 | 0.586 |
| Others | +11.83 | 0.288 |
BCVA, best-corrected visual acuity; VEGF, vascular endothelial growth factor; AMD, age-related macular degeneration; DME, diabetic macular edema; RVO, retinal vein occlusion.